According to the World Health Organisation, around 350 million people suffer due to depression.
Number of antidepressants are prescribed for the treatment. And many FDA drugs are found to cause serious side effects.
‘New findings related to antidepressant drugs may show promise in treating depression.’
A research team from Texas Tech Health Science Center led by Michaela Jansen, Pharm.D., Ph.D., recently examined the ability of bupropion and its metabolite to block the action of serotonin type 3A receptor (5HT3ARs).
Previous studies on Bupropion were based on the discovery of reuptake inhibitors as molecular targets for the drug within the brain network and in 1999 the drug was also found to inhibit nicotinic receptors and block smoking cessation.
The recent study of the drug was published in the september issue of the journal Neuropharmacology
Serotonin type 3A receptors are pentameric (five membered) ligand gated ion channels (pLIC) and implicate the development of anxiety and psychiatry disorders like anxiety, depression, addiction, irritable bowel syndrome and cognitive function.
Akash Pandhare, M.D., Ph.D, author and scientist at the TTUHSC Department of Cell Physiology and Molecular Biophysics, "For a long time, the blockade of dopamine and norepinephrine reuptake by the antidepressant bupropion within the hypofunctioning central nervous system monoamine systems has remained one of the pharmacological underpinnings for its therapeutic efficacy."
"This study for the first time established the 5-HT3ARs as a hitherto unidentified molecular target of bupropion." he added.
The research findings were also found to demonstrate clinical relevant concentration of receptor blockade by both the drug and its metabolite. The findings will now be a part of the pharmacy and medical text books.
The author also said that psychiatrist will now have a better understanding of the mechanism behind antidepressant drugs before prescribing.